Drug development - Lupus drug company asks FDA for second chance

被引：4

作者：

Couzin, J

机构：

来源：

SCIENCE | 2005年 / 307卷 / 5711期

关键词：

D O I：

10.1126/science.307.5711.835

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

The safety of LJP 394, produced by La Jolla Pharmaceutical Company, for the treatment of lupus is discussed. FDA approval, clinical trials, and adverse effects are also discussed.

引用

页码：835 / 835

页数：1

共 50 条

[41] Drug development - Evotec OAI takes stake in new drug company
McCoy, M
CHEMICAL & ENGINEERING NEWS, 2002, 80 (42) : 15 - 15
[42] FDA allows second experimental drug to be tested in Ebola patients
McCarthy, Michael
BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
[43] FDA user fee renewal addresses drug shortages, new drug development
Wechsler, Jill
FORMULARY, 2012, 47 (03) : 125 - 126
[44] A Comparison of FDA and EMA Drug Approval: Implications for Drug Development and Cost of Care
Howie, Lynn J.
Hirsch, Bradford R.
Abernethy, Amy P.
ONCOLOGY-NEW YORK, 2013, 27 (12): : 1195 - +
[45] FDA: Early stage drug development costs trigger higher drug costs
2018, UBM Medica Periodical Publication (42)
[46] DRUG PANEL ASKS PROTECTION FOR VOLUNTEERS
VEITCH, A
SCIENTIST, 1987, 1 (26): : 7 - 7
[47] METABOLOMICS/LIPIDOMICS FOR DRUG DEVELOPMENT IN A PHARMACEUTICAL COMPANY
Satomi, Yoshinori
DRUG METABOLISM REVIEWS, 2015, 47 : 17 - 17
[48] Company managed to block development of generic drug
Kmietowicz, Zosia
BRITISH MEDICAL JOURNAL, 2008, 336 (7644): : 576 - 576
[49] The innovative pharmaceutical company and drug development - Comment
Drews, J
Ryser, S
CHEMTECH, 1998, 28 (12) : 7 - 9
[50] A Second Chance: Reenactment and Recovery Narratives in a Peruvian Drug Rehabilitation Center
Silverstein, Sydney M.
MEDICAL ANTHROPOLOGY QUARTERLY, 2021, 35 (02) : 190 - 208

← 1 2 3 4 5 →